Amarin v. Hikma
View Brief
AAM Applauds Senate Judiciary Committee Efforts to Protect Patients and Skinny Labeling
Submits formal statement for the record for hearing on drug pricing in support of proposed protections to ensure patients have access to safe and affordable generic medicines and biosimilars WASHINGTON (May 21, 2024) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, and the Biosimilars Council, a division of […]
AAM Statement on U.S. Supreme Court Decision to Decline Hearing GSK v. Teva
WASHINGTON, D.C. (May 15, 2023) – The Association for Accessible Medicines Interim CEO, David Gaugh, today released the following statement regarding the U.S. Supreme Court’s decision to decline hearing the GSK v. Teva case: “AAM is disappointed that the U.S. Supreme Court denied certiorari in the GSK v. Teva case. AAM will continue to support the Hatch-Waxman […]
Pharmaceutical Shipping Costs Spike in Response to Global COVID-19 Pandemic
AAM Survey of Biosimilars and Generic Drug Manufacturers Reveals Average of 224% Increase In Cost of Transporting Drugs WASHINGTON, DC (April 30, 2020) — The cost of shipping pharmaceuticals to the United States has risen sharply as a result of the global coronavirus pandemic, according to a new survey of generic drug manufacturers conducted by the […]
AAM Statement on FDA Withdrawal of Generic Drug Labeling Rule
WASHINGTON DC (December 13, 2018) – “AAM applauds FDA Commissioner Scott Gottlieb and the agency for prioritizing consumer access to safe, high-quality, affordable generic medicines by withdrawing its proposed labeling rule. The agency correctly recognized the need for consistency and the potential for adverse consequences. The FDA’s action further exemplifies its focus on the best […]
